Our mission at Accurius is to fundamentally transform cancer treatment and improve outcomes for cancer patients. Our team of leading researchers and experienced commercial leaders is poised to deliver on the full potential of Oncolytic Immunotherapy.

We’ve combined innovative oncolytic immunotherapy science and cutting-edge
drug delivery technology to develop a first-of-a-kind treatment for metastatic Non-Small Cell Lung Cancer (mNSCLC) and other cancers metastasizing to the lung.

Each year, more than 100,000 people in the United States present with or advance into mNSCLC. Unfortunately, only about 7% of these patients are expected to live more than 5 years. At Accurius, we’re fighting to provide better odds for these patients to enjoy longer and healthier lives.